Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker

Patent Number: 6828145

Classically hematopoietic stem cells are purified based on expression of markers such CD34 or c-kit. This patent teaches that hematopoietic stem cells can also be further purified by selecting cells that lack expression of MHC I. The lack of expression of class I may have to do with the presumed weaker immunogenecity of hematopoietic stem cells.

Currently this invention doesnt seem to be practiced clinically, this invention could be used not only for hematopoietic stem cell transplantation, but also for other regenerative situations in which stem cells may be transplanted across allogeneic barriers.

View this patent on the USPTO website.